Raise closed, search for fresh raises on Seedstage

Lebanon, NH

Providing implantable biosensors for real-time tumor monitoring to accelerate cancer drug discovery.

• Mission: Accelerating cancer drug discovery by providing real-time biosensors that monitor tumor dynamics and immune responses during treatment development.  
• Innovation: Implantable IRIS biosensors offering valuable, real-time data to guide cancer researchers in drug development and decision-making.  
• Market Opportunity: Positioned to capitalize on the expanding $197 billion drug discovery technology market, offering a critical solution for preclinical cancer research.  
• Strategic Collaborations: Successful deployments at prestigious institutions such as Dartmouth and Yale, generating initial revenue and validating the technology.  
• Impact on Drug Development: Aims to significantly shorten the early phases of cancer drug discovery by providing more accurate, real-time insights into tumor behavior.  
• Growth Potential: Focused on refining its biosensing technology to meet the evolving needs of cancer researchers, contributing to faster advancements in cancer treatments.

Lodestone Biomedical is a biotechnology company that focuses on accelerating cancer drug discovery by providing implantable biosensors capable of monitoring real-time changes in tumors. The company’s technology, known as IRIS, helps cancer researchers observe immune responses during treatment development, offering valuable insights into tumor dynamics. These biosensors enable data-driven decision-making, which can significantly expedite the early phases of cancer drug discovery. By addressing a critical gap in existing cancer research tools, Lodestone aims to revolutionize the process of developing effective cancer therapies.

The global market for drug discovery technologies is expected to grow substantially, and Lodestone’s real-time biosensing solutions are positioned to capitalize on this trend. The company’s products, such as the IRIS biosensors, have already been deployed in preclinical research at prestigious institutions like Dartmouth and Yale. These collaborations have generated initial revenue and helped validate Lodestone’s technology. Moving forward, the company is focused on refining its products to meet the evolving needs of cancer researchers, with the goal of accelerating the development of novel cancer treatments and contributing to breakthroughs in the fight against cancer.

Company Info

Lodestone Biomedical develops implantable biosensors for real-time tumor monitoring to accelerate drug discovery and cancer treatment advancements.

Lodestone Biomedical is a biotechnology company focused on providing implantable biosensors designed to offer real-time monitoring of immune responses in cancer research. The company’s technology, the Immune Response Indication System (IRIS), allows researchers to observe tumor dynamics during drug discovery, accelerating the development of cancer therapies. Lodestone’s biosensors provide valuable insights into tumor behavior, enabling more informed decisions during early-stage treatment development.

The company has already demonstrated success through partnerships with prestigious institutions such as Dartmouth and Yale, generating revenue through NIH and CRI-funded projects. With the global drug discovery technology market projected to reach $197 billion by 2029, Lodestone is positioned to capitalize on the growing demand for innovative preclinical research tools. The company’s ongoing efforts are dedicated to refining its biosensing technology to improve its sensitivity and reliability, ultimately supporting drug developers in advancing cancer treatments faster and more efficiently.